US$ 20.35
glp 1 ckd Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis Preventing diabetic kidney disease progression:
Description
The findings were published Wednesday in the Journal of the American Medical Association

8,129,343 protects the chemical structure of the semaglutide molecule, meaning no one else is allowed to manufacture that specific sequence of amino acids until the patent expires in December 2031

Patient Impact Patients are the ultimate beneficiaries (or victims) of PA policy

A patient-centered strategy does more than improve adherence

Annals of Translational Medicine

Melville NA
